Trials / Terminated
TerminatedNCT02453035
DESolve® X-Pand Global Post Market Registry
X-Pand is Intended to Use the DESolve Scaffold System in Treatment of CAD Patients, by Including "Real World" Use of the DESolve Scaffold Over a Broad Spectrum of Geographies, A Wide Variety of Practicing Clinicians & A Minimum Degree Of Selection Criteria
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 154 (actual)
- Sponsor
- Elixir Medical Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The X-Pand Registry is intended to facilitate analysis of acute \& long-term safety as well as treatment outcomes with DESolve in patients with CAD.
Detailed description
The Xpand Registry is a single-arm, multi-center, clinical Follow up study of patients with significant coronary stenosis who are treated with a commercially available DESolve Scaffold. The Registry is an observational study. The patients should be treated according to the current DESolve IFU, professional societies guidelines \& internal hospital guidelines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | PTCA - Desolve Scaffold | Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold |
Timeline
- Start date
- 2015-05-13
- Primary completion
- 2017-03-31
- Completion
- 2017-04-30
- First posted
- 2015-05-25
- Last updated
- 2021-04-26
Locations
5 sites across 2 countries: Germany, Netherlands
Source: ClinicalTrials.gov record NCT02453035. Inclusion in this directory is not an endorsement.